A PARALLEL-GROUP PHASE 4, OPEN-LABEL, TWO-ARM STUDY TO ASSESS THE SAFETY ANDEFFICACY OF INTRAVITREAL (IVT) AFLIBERCEPT WITH PROACTIVE CUSTOMIZED TREATMENT INTERVALS IN PATIENTS ¿50 YEARS OF AGE WITH NO FLUID DUE TO CHOROIDAL NEOVASCULARIZATION (CNV) LESIONS SECONDARY TO NEOVASULAR (WET) AGE-RELATED MACULAR DEGENERATION (NAMD) FOLLOWING TREATMENT INITIATION WITH AFLIBERCEPT
- Registry ID
- 21912
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE4
- Study type
- INTERVENTIONAL
- Sponsor
- BAYER INC
- Start date
- 2023-03-07
- Completion date
- 2023-07-16
- Last update
- 2022-09-07
Conditions
- MACULAR DEGENERATION
- CHOROIDAL NEOVASCULARIZATION
- NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Related clinical trials
- A RANDOMIZED, DOUBLE MASKED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGE FINDING STUDY TO ASSESS THE EFFICACY AND SAFETY OF FWY003 IN PARTICIPANTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
- A RANDOMIZED, CONTROLLED, PARTIALLY MASKED, PHASE 3B STUDY TO ASSESS THE INJECTION BURDEN, EFFICACY, SAFETY, AND LONG-TERM PRESERVATION OF VISUAL ACUITY OF SURABGENE LOMPARVOVEC (ABBV-RGX-314) IN A REAL-WORLD CONTEXT IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- A PHASE 3, RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED TRIAL OF A SINGLE LNTRAVITREAL INJECTION OF 4D-150 IN ADULTS WITH MACULAR NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION (4FRONT-1)
- A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM CONTROLLED, REFERENCE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF ONL1204 IN PATIENTS WITH GEOGRAPHIC ATROPHY (GA) ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION (AMD)
- HIGH DOSE (HD) AFLIBERCEPT SWITCH IN NAMD:
TO LOAD OR MAINTAIN? (HEIRLOOM)
- A PHASE IIIB/IV, MULTICENTER, RANDOMIZED, OPEN-LABEL, TWO ARM STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND
DURABILITY OF FARICIMAB ADMINISTERED UP TO EVERY 24 WEEKS
IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR
DEGENERATION (CONSTANCE)
View on source registry